Propel Bio Partners is a global venture fund focused on high-potential businesses in the biosciences sector. Established in March 2022 by Dr. Leen Kawas and Richard Kayne, the firm targets companies that are ready to pursue clinical trials or regulatory approval. Propel Bio Partners typically invests in Seed and Series A rounds, providing capital to help develop disruptive technologies within the biosciences space.

Notable portfolio companies include OmniVis and Persephone Biosciences. The firm is led by Dr. Leen Kawas, known for her expertise in biosciences, and Richard Kayne, a seasoned investor. Propel Bio Partners emphasizes not only financial support but also strategic guidance to help portfolio companies navigate the complexities of clinical trials and regulatory landscapes. This combination of capital and mentorship aims to accelerate the growth and success of innovative bioscience ventures.